SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (AMEX:BSM) today announced that a major presentation was delivered by Dr. Rolf Issels at the 19th International Congress on Anti-Cancer Treatment (ICACT) held this month in Paris, France, addressing the use of hyperthermia therapy (through the BSD-2000) to reduce the risk of early disease progression in high-grade soft-tissue sarcomas. The results reported were from an analysis of a phase 3 clinical study in which 341 high-grade sarcoma patients were enrolled and randomized into two groups, the control group receiving chemotherapy alone and the experimental group receiving chemotherapy plus hyperthermia. The study concluded that disease-free survival and local progression-free survival were significantly improved in the experimental group.
